NEW YORK, March 16, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the INSYS Therapeutics, Inc. ("INSYS" or the "Company") (NASDAQ: INSY). Such investors are advised to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/insy.
The investigation concerns whether INSYS and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On March 15, 2017, after-market hours, INSYS announced that it postpone filing its financial results for the quarter and year ended December 31, 2016. INSYS told investors that "[t]he Audit Committee of the Company's Board of Directors has been conducting an independent review of the Company's processes related to estimation of, and increases to, certain sales allowances recorded during 2016, with a potential reduction of 2015 net revenue and pre-tax income not expected to exceed $5 million, as well as extended payment terms offered to certain customers during the third quarter of 2016." Following this news, INSYS stock has dropped as much as $0.75 per share, or 7.11%, during intraday trading on March 16, 2017.
If you are aware of any facts relating to this investigation, or purchased INSYS shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/insy. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-insys-therapeutics-inc-insy-300424987.html
SOURCE Bronstein, Gewirtz & Grossman, LLC